The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation

Autor: L, Rooshenas, LJ, Scott, JM, Blazeby, CA, Rogers, KM, Tilling, S, Husbands, C, Conefrey, N, Mills, RC, Stein, C, Metcalfe, AJ, Carr, DJ, Beard, T., Davis, S, Paramasivan, M, Jepson, K, Avery, D, Elliott, C, Wilson, JL, Donovan, Rogers, Chris A., Andrews, Robert, Blazeby, Jane M., Byrne, James, Donovan, Jenny L., Kelly, Jamie, Mazza, Graziella, Mahon, David, Noble, Hamish, Reeves, Barnaby C., Thompson, Janice L., Wordsworth, Sarah, Welbourn, Richard, Beard, David, Carr, Andrew, Cook, Jonathan, Cooper, Cushla, Dean, Benjamin, Gray, Alastair, Gwilym, Stephen, Judge, Andrew, Merritt, Naomi, Moser, Jane, Rees, Jonathan, Rombach, Ines, Savulescu, Julian, Tracey, Irene, Wartolowska, Karolina, Tan, Wei, Mills, Nicola, Karantana, Alexia, Sprange, Kirsty, Duley, Lelia, Elliott, Daisy, Hollingworth, William, Montgomery, Alan A., Davis, Tim, Stein, Rob, Bartlett, John, Cameron, David, Campbell, Amy, Canney, Peter, Dunn, Janet, Earl, Helena, Falzon, Mary, Francis, Adele, Hall, Peter, Harmer, Victoria, Higgins, Helen, Hiller, Louise, Hughes-Davies, Luke, Hulme, Claire, Macpherson, Iain, Makris, Andreas, Marshall, Andrea, McCabe, Christopher, Morgan, Adrienne, Pinder, Sarah, Poole, Christopher, Provenzano, Elena, Rea, Daniel, Stallard, Nigel, Avery, Kerry NL., Barham, C Paul, Berrisford, Richard, Elliott, Jackie, Falk, Stephen J., Goldin, Rob, Hanna, George, Hollowood, Andrew A., Krysztopik, Richard, Metcalfe, Chris, Noble, Sian, Sanders, Grant, Streets, Christopher G., Titcomb, Dan R., Wheatley, Tim

ObjectiveTo evaluate the impact of the Quintet Recruitment Intervention (QRI) on recruitment in challenging randomized controlled trials (RCTs) that have applied the intervention. The QRI aims to understand recruitment difficulties, and then implemen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::a3d1dbfb518c2c540a5d5af0b01c691b

The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy

Autor: Mark Bower, Rc, Stein, Hedley A, Davenport J, Colston K, Rc, Coombes

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::357681382a0f52e46a924050afc60116
https://pubmed.ncbi.nlm.nih.gov/1879049

Multistate Gene Cluster Switches Determine the Adaptive Mitochondrial and Metabolic Landscape of Breast Cancer.

Autor: Menegollo M; Department of Biomedical Sciences, University of Padova, Padova, Italy., Bentham RB; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Henriques T; Department of Biomedical Sciences, University of Padova, Padova, Italy., Ng SQ; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Ren Z; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Esculier C; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Agarwal S; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Tong ETY; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Lo C; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Ilangovan S; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Szabadkai Z; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom., Suman M; Department of Biomedical Sciences, University of Padova, Padova, Italy., Patani N; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom.; The Francis Crick Institute, London, United Kingdom., Ghanate A; The Francis Crick Institute, London, United Kingdom., Bryson K; Department of Computer Sciences, University College London, London, United Kingdom., Stein RC; Department of Oncology, University College London Hospitals, London, United Kingdom.; UCL Cancer Institute, University College London, London, United Kingdom., Yuneva M; The Francis Crick Institute, London, United Kingdom., Szabadkai G; Department of Biomedical Sciences, University of Padova, Padova, Italy.; Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom.; The Francis Crick Institute, London, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2024 Sep 04; Vol. 84 (17), pp. 2911-2925.

Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training.

Autor: Bartlett JMS; Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.; Edinburgh Cancer Research Centre, Edinburgh, United Kingdom., Bayani J; Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Kornaga EN; Tom Baker Cancer Centre, Calgary, Alberta, Canada., Danaher P; Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Crozier C; Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Piper T; Edinburgh Cancer Research Centre, Edinburgh, United Kingdom., Yao CQ; Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada., Dunn JA; Warwick Medical School, University of Warwick, Coventry, United Kingdom., Boutros PC; Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Stein RC; UCL (University College London) and National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom.

Publikováno v: PloS one [PLoS One] 2020 Sep 03; Vol. 15 (9), pp. e0238593. Date of Electronic Publication: 2020 Sep 03 (Print Publication: 2020).

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Autor: Schmid P; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Barts Hospital NHS Trust, London, United Kingdom., Abraham J; Velindre National Health Service (NHS) Trust, Cardiff, United Kingdom., Chan S; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Wheatley D; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom., Brunt AM; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom., Nemsadze G; Institute of Clinical Oncology, Tbilisi, Georgia., Baird RD; Cancer Research UK Cambridge Centre, Cambridge, United Kingdom., Park YH; Samsung Medical Centre, Seoul, Republic of Korea., Hall PS; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom., Perren T; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Stein RC; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London, London, United Kingdom., Mangel L; Institute of Oncology, Medical University of Pécs, Pecs, Hungary., Ferrero JM; Centre Antoine Lacassagne, Nice, France., Phillips M; Barts Hospital NHS Trust, London, United Kingdom., Conibear J; Barts Hospital NHS Trust, London, United Kingdom., Cortes J; Ramon y Cajal University Hospital, Madrid, Spain., Foxley A; AstraZeneca, Cambridge, United Kingdom., de Bruin EC; AstraZeneca, Cambridge, United Kingdom., McEwen R; AstraZeneca, Cambridge, United Kingdom., Stetson D; AstraZeneca, Waltham, MA., Dougherty B; AstraZeneca, Waltham, MA., Sarker SJ; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Prendergast A; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., McLaughlin-Callan M; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Burgess M; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Lawrence C; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Cartwright H; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Mousa K; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Turner NC; Institute of Cancer Research, London, United Kingdom.; Royal Marsden Hospital, London, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Feb 10; Vol. 38 (5), pp. 423-433. Date of Electronic Publication: 2019 Dec 16.